G-Protein Coupled Receptor (GPCR) Targeting Market is segmented By Product(Cell Lines, Detection Kits, Cell Culture Reagents, Ligands), By Application Segment (Cancer Research, CNS Research, Metabolic Research, Cardiovascular Research, Respiratory Research, Inflammation Research, Other Application), By End-user (cAMP Functional Assays, Calcium Functional Assays, β-Arrestin Functional Assays, Radioligand Binding and GTPγS Functional Assays, Internalization Assays, Trafficking Assays, Other Assays), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
G-protein Coupled Receptor (GPCR) Targeting Market Outlook
G-protein Coupled Receptor (GPCR) Targeting Market is Expected to reach at a high CAGR of 6.40% during the forecast period (2024-2031).
G-protein coupled receptor (GPCR), also called seven-transmembrane receptor or heptahelical receptor, is a protein located in the cell membrane that binds extracellular substances and transmits signals from these substances to an intracellular molecule called a G protein (guanine nucleotide-binding protein). They are found in the cell membranes of many organisms, including mammals, plants, microorganisms, and invertebrates. Some examples of GPCRs include beta-adrenergic receptors, which bind epinephrine, prostaglandin E2 receptors, which bind inflammatory substances called prostaglandins; and rhodopsin, which contains a photoreactive chemical called retinal, which response to light signals received by rod cells in the eye.
G-Protein Coupled Receptor (GPCR) Targeting Market Scope
| Metrics | Details |
| Market CAGR | 6.40% |
| Segments Covered | By Product, By Application Segment, By End-user, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More: Download Sample
G-Protein Coupled Receptor (GPCR) Targeting Market Dynamics
The global G-protein coupled receptor (GPCR) targeting market growth is driven by the rising number of cancer cases and the rising prevalence of lifestyle-related issues, such as cardiovascular infections and respiratory problems. G-protein coupled receptors (GPCRs) are exceptionally helpful in the innovative work of newer medication substances. Furthermore, the increasing government funding for R&D activities in drug discovery and development is anticipated to drive market growth.
Growing demand for GPCR assays in drug discovery studies is expected to drive market growth.
GPCRs respond to a wide range of external stimulus and are a part of several disease etiologies. The wide application of techniques, such as High-Throughput Screening (HTS), combinatorial chemistry, and medicinal chemistry, has led to identifying ligands that modulate the target's activity. in turn, has resulted in the effective identification of pharmaceutically relevant drug candidates, which drives the adoption of these receptors in the drug discovery processes. The presence of many approved drugs and drugs under clinical and preclinical studies, which target these receptors, boosts the demand for GPCR screening assays in drug development. Moreover, an increasing number of allosteric modulators, biological drugs, and biased agonists that target these receptors accelerate the demand for associated assays.
Moreover, advancements in the computational approaches to streamline receptor structure contribute to the development of effective drug discovery methods. Researchers from the University of Southern California, the Skolkovo Institute of Science & Technology, and the Moscow Institute of Physics & Technology designed a thermally stable GPCR by a computational method to formulate new drugs.
Companies in the market focus more on research to explore the novel biological functions of the approved and withdrawn drug candidates. These can be used for other indications as well. Research based on a custom-designed oligonucleotide GPCR chip by Arena Pharmaceuticals has identified a relative expression of more than seven hundred receptors of high therapeutic importance. This research would further utilize this research for the discovery of small molecules.
Complexity in the purification of GPCRs is likely to hinder market growth.
The purification of GPCRs is complicated by factors including low abundance, poor stability and structural plasticity leading to multiple conformations. Despite this, several non-rhodopsin GPCR structures have been solved from protein purified using a broadly similar strategy of single or numerous affinity steps. These factors are likely to hamper market growth.
Global G-Protein Coupled Receptor (GPCR) Targeting Market- Industry Analysis
Supply Chain Analysis
COVID-19 Impact Analysis
The pandemic COVID-19 viral infection is often associated with severe respiratory and neurological complications, cardiovascular problems, microvascular and endothelial disorders, and gastrointestinal diseases. According to the journal published in PubMed, assumed that GPCR-fAABs play an essential role in developing and maintaining post-COVID symptoms. These GPCR-fAABs persistently stimulate their corresponding receptors, and the fAABs themselves inhibit the receptors' normal, physiological, cell-protective desensitization.
In other diseases, such as idiopathic dilated cardiomyopathy (here it is the autoantibody targeting the beta1-adrenoceptor), GPCR-fAABs play a significant role in the pathogenesis of the disease. Additionally, removing these fAABs by immunoadsorption improved cardiac function and a substantial increase in survival rate. These factors are expected to drive the demand for GPCR targeting the market.
G-Protein Coupled Receptor (GPCR) Targeting Market Segment Analysis
The cancer research segment is expected to hold the largest share in this market segment.
More than 700 genes are identified as the G-protein coupled receptors, which form the most significant protein superfamily in the human genome. GPCRs play a vital role in interfering with various physiological events, from sensory modulations to hormonal responses. Recently, a key focus on basic and clinical investigators demonstrated that signaling through GPCRs affects the multiple aspects of cancer biology, such as invasion, migration, and vascular remolding. Hence, the development of GPCR-targeted drugs will provide a novel therapeutic strategy in treating various types of cancers. As GPCR signaling is an essential contributor to tumor growth and metastasis, discerning how G protein-coupled receptor kinases (GRKs) regulate GPCR activity in cancer cells may significantly improve the understanding of tumorigenesis and oncogenesis and help develop novel anti-cancer therapies.
G-Protein Coupled Receptor (GPCR) Targeting Market Geographical Analysis
North America region holds the largest market share of global G-protein coupled receptor (GPCR), targeting the market.
The Asia-Pacific region is expected to grow at a significant rate during the forecast period, owing to the economic development of the countries, such as China and India, along with the increasing government investment in the biotechnology and biopharmaceutical sector, increasing life expectancy, rising per capita income, and unmet market needs in the region. Asia Pacific is anticipated to be the fastest-growing regional market due to several emerging companies, such as Sosei Heptares and NB Health Laboratory. The number of growth initiatives the companies undertake to improve their market presence drives regional growth.
G-Protein Coupled Receptor (GPCR) Targeting Market Competitive Landscape
G-protein coupled receptor targeting market is highly competitive with the presence of local as well as international companies. Some of the key players which are contributing to the growth of the market include Abcam plc, Enzo Life Sciences, Inc, Promega Corporation, PerkinElmer Inc, Thermo Fisher Scientific, Eurofins DiscoverX Products, WuXi AppTec (HD Biosciences Co. Ltd), BioInvenu Inc, Danaher Corporation (Molecular Devices LLC) and Merck KGaA. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which contribute to the growth of the Immuno oncology assays globally. For instance, in June 2018, Amgen's erenumab secured FDA approval as the first G-protein coupled receptor-targeted antibody.
Key Companies to Watch
Thermo Fisher Scientific Inc
Overview: Thermo Fisher Scientific Inc is one of the world leaders serving science, with approximately $40 billion annual revenue. It has a global team of more than 100,000 colleagues who delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Product Portfolio: It includes products like Tango GPCR Assay System, GeneBLAzer Assays for GPCRs etc.
Tango GPCR Assay System: The Tango GPCR Assay System is a proprietary platform based upon ligand binding to a specific G protein-coupled receptor (GPCR) that triggers desensitization, a process mediated by the recruitment of protease-tagged arrestin proteins to the activated receptor.
